S. Percell

发表

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study

R. Postier, T. Butler, K. Reinhart, 2001, Critical care medicine.

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

J. McVernon, H. Marshall, D. Toneatto, 2015, Vaccine.

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.

G. Poland, A. Podda, S. Frey, 2003, Vaccine.

Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

T. Odrljin, K. Reisinger, S. Block, 2014, The Pediatric infectious disease journal.

Immunogenicity and Safety of Combined Tetanus, Reduced Diphtheria, Acellular Pertussis Vaccine when Co-Administered with Quadrivalent Meningococcal Conjugate and Human Papillomavirus Vaccines in Healthy Adolescents

R. Gasparini, A. Garscadden, W. Johnston, 2014 .

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.

R. Sekulovich, S. Frey, R. Burke, 1999, The Journal of infectious diseases.

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

C. Sprung, R. Postier, C. Doig, 2003, JAMA.

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

W. Britt, S. Boppana, R. Sekulovich, 1999, The Journal of infectious diseases.

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

C. Sprung, S. Opal, B. Light, 2013 .